CEO Hanna Sjöström will attend to engage with investors and potential industry partners, focusing on the company’s preparations for the anticipated U.S. market launch of Neola®, its advanced continuous lung monitoring device designed to improve care for preterm born babies in neonatal intensive care units.

"The J.P. Morgan Healthcare Conference offers an invaluable opportunity to strengthen Neola Medical’s position as we advance toward commercialization. This event allows us to showcase our progress, forge meaningful partnerships, and align with key stakeholders who are essential to our U.S. market entry and scaling efforts.” says Hanna Sjöström, CEO of Neola Medical.

As Neola Medical prepares for FDA approval, the company is actively laying the foundation for successful commercialization in the U.S. This includes strategic efforts to demonstrate the technology’s value in clinical settings, build a strong sales presence, and establish effective market entry channels to support future growth.

For more information about the J.P. Morgan Healthcare Conference: https://www.jpmorgan.com/solutions/cib/insights/health-care-conference